Hong-Gyun Wu
Seoul National University · 医学
研究室紹介
Professor Hong-Gyun Wu's research lab specializes in radiation oncology and cancer therapeutics, with a focus on improving radiotherapy outcomes through advanced imaging, treatment planning, and biomarker discovery. The lab investigates dynamic changes in immune checkpoint molecules like PD-L1 during cancer treatment, evaluates the impact of chemotherapy on immune modulation, and compares advanced radiotherapy techniques such as IMRT, VMAT, and MRI-guided radiotherapy for optimal tumor control and reduced toxicity. Their work spans from translational research in head and neck cancers to clinical outcomes in early glottic cancer and rectal cancer, emphasizing personalized and precision radiotherapy strategies.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15// Chan-Young Ock 1, * , Sehui Kim 2, * , Bhumsuk Keam 1, 3 , Miso Kim 1 , Tae Min Kim 1, 3 , Jin-Ho Kim 4 , Yoon Kyung Jeon 2 , Ju-Seog Lee 5 , Seong Keun Kwon 6 , J. Hun Hah 6 , Tack-Kyun Kwon 6 , Dong-Wan Kim 1, 3 , Hong-Gyun Wu 4 , Myung-Whun Sung 6 , Dae Seog Heo 1, 3 1 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea 2 Department of Pathology, Seoul National University Hospital Seoul, Korea 3 Cancer Research Institute, Seoul National University College of M
Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment. Paired HNSCC tissues prior to and after cisplatin-based treatment were evaluated to determine PD-L1 protein expression by immunohistochemistry. Among the 35 HNSCC patient samples, PD-L1 expression status changed after treatment in 37.1% (13/35) of samples.
The choice of treatment of ATC and PDTC could be modified according to resectability and lymphatic invasion of the cancer.
BACKGROUND: To compare the acute gastrointestinal (GI) and genitourinary (GU) toxicity profiles between intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in rectal cancer patients treated with neoadjuvant chemoradiation (NCRT) using meta-analysis and pooled-analysis from published articles. METHODS: Literature search was performed in PubMed and EMBASE from inception to March 2017. The odd ratios (ORs) were calculated and random effects model was used fo
The aim of this study was to compare the plan quality of magnetic-resonance image-based intensity modulated radiation therapy (MRI-based-IMRT) with the MRIdian Linac system to that of volumetric modulated arc therapy (VMAT) with the TrueBeam STx system for lung stereotactic ablative radiotherapy (SABR). A total of 22 patients with tumors located in the lower lobe were retrospectively selected for the study. For each patient, both the MRI-based-IMRT and VMAT plans were generated using an identica
To screen the differentially expressed microRNAs related to radio-resistance, we compared the microRNA profiles of lung cancer cells with different responses to ionizing radiation (IR). Of 328 microRNAs in microarray, 27 microRNAs were differentially expressed in NCI-H460 (H460) and NCI-H1299 (H1299) cells. Among them, let-7g was down-regulated in radio-resistant H1299 cells, and the level of let-7g was higher in radio- sensitive cells like Caski, H460, and ME180 in qRT-PCR analysis than in radi
PURPOSE: This study evaluates the long-term results of definitive radiotherapy (RT) for early glottic cancer. Clinical and treatment factors related to local control and patterns of failure are analyzed. MATERIALS AND METHODS: We retrospectively reviewed 222 patients with T1-2N0 squamous cell carcinoma of the glottic larynx treated with definitive RT from 1981 to 2010. None of the patients received elective nodal RT or combined chemotherapy. The median total RT dose was 66 Gy. The daily fraction